» Articles » PMID: 35383138

Signal Crosstalk and the Role of Estrogen Receptor Beta (ERβ) in Prostate Cancer

Overview
Journal Med Sci Monit
Date 2022 Apr 6
PMID 35383138
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer remains the most prevalent cancer among men worldwide; however, as a sex hormone-dependent cancer, sex hormones and their receptor signaling play an important role in the development and progression of cancer. Most current treatment options for prostate cancer thus revolve around the inhibition of androgen signaling (eg, ADT), which, although effective in the early stages, eventually progresses to treatment-resistant prostate cancer with no effective follow-up options. Recent studies have shown that among the nuclear receptor family members, in addition to androgen receptors, estrogen receptor (ER) plays an important biological function as a transcription factor and regulatory protein in various cancers, acting either directly or indirectly by forming homodimers or heterodimers with ligands. In this paper, we review the application of ERß in animal models and in vitro experiments in the last 5 years, as well as the presence and role of some of its splice variants. We summarize the overview and update of ERß in prostate cancer, and provide a corresponding analysis of some current research disagreements. Its crosstalk action on some important cancer growth-related signaling pathways (eg, TGF-ß and ERK), regulation of downstream target proteins (eg, nuclear translocation of EGFR and expression of oncogenic -related protein MMP-2), and interactions with related ERß co-regulators (eg, ZFHX3), agonists, and antagonists in prostate cancer are highlighted, and the resulting effects on tumor progression are described. In addition, the paper describes its current potential clinical application as a novel therapeutic strategy and some of the challenges it faces.

Citing Articles

Nanostructures for site-specific delivery of oxaliplatin cancer therapy: Versatile nanoplatforms in synergistic cancer therapy.

Bagheri M, Zandieh M, Daryab M, Samaei S, Gholami S, Rahmanian P Transl Oncol. 2023; 39:101838.

PMID: 38016356 PMC: 10698329. DOI: 10.1016/j.tranon.2023.101838.


Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function.

Belluti S, Imbriano C, Casarini L Cancers (Basel). 2023; 15(18).

PMID: 37760622 PMC: 10526871. DOI: 10.3390/cancers15184653.


Insight into the Potential Mechanisms of Endocrine Disruption by Dietary Phytoestrogens in the Context of the Etiopathogenesis of Endometriosis.

Szukiewicz D Int J Mol Sci. 2023; 24(15).

PMID: 37569571 PMC: 10418522. DOI: 10.3390/ijms241512195.


Effects on Serum Hormone Concentrations after a Dietary Phytoestrogen Intervention in Patients with Prostate Cancer: A Randomized Controlled Trial.

Ahlin R, Norskov N, Nybacka S, Landberg R, Skokic V, Stranne J Nutrients. 2023; 15(7).

PMID: 37049632 PMC: 10097251. DOI: 10.3390/nu15071792.


Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor.

Souza D, Macheroni C, Pereira G, Vicente C, Porto C Front Endocrinol (Lausanne). 2023; 14:1124111.

PMID: 36936148 PMC: 10020622. DOI: 10.3389/fendo.2023.1124111.


References
1.
Moussa M, Papatsoris A, Chakra M, Sryropoulou D, Dellis A . Pharmacotherapeutic strategies for castrate-resistant prostate cancer. Expert Opin Pharmacother. 2020; 21(12):1431-1448. DOI: 10.1080/14656566.2020.1767069. View

2.
Rice L, Lepler S, Pampo C, Siemann D . Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells. Clin Exp Metastasis. 2011; 29(2):133-42. DOI: 10.1007/s10585-011-9436-2. View

3.
Vanderschueren D, Vandenput L, Boonen S, Lindberg M, Bouillon R, Ohlsson C . Androgens and bone. Endocr Rev. 2004; 25(3):389-425. DOI: 10.1210/er.2003-0003. View

4.
Faria M, Shepherd P, Pan Y, Chatterjee S, Navone N, Gustafsson J . The estrogen receptor variants β2 and β5 induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling. Oncotarget. 2018; 9(91):36273-36288. PMC: 6284737. DOI: 10.18632/oncotarget.26345. View

5.
Grindstad T, Skjefstad K, Andersen S, Ness N, Nordby Y, Al-Saad S . Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome. Sci Rep. 2016; 6:33114. PMC: 5017140. DOI: 10.1038/srep33114. View